Literature DB >> 27406897

SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes.

Corrado Tinterri1, Giuseppe Canavese1, Paolo Bruzzi2, Beatrice Dozin3.   

Abstract

Sentinel lymph node biopsy alone is the current surgical axillary treatment for early-stage breast cancer patients with a negative sentinel lymph node (SLN). The possibility to omit axillary dissection also in presence of positive SLNs has been promoted by the American College of Surgeons Oncology Group (ASOCOG) Z0011 randomized trial. Several limitations and evidences of potential selection bias made this trial fairly controversial. Stronger evidence than currently available is needed on the safety of foregoing axillary dissection in well-defined populations of patients with positive SLNs. The Italian multicentre SINODAR ONE randomized trial here presented was designed with this aim.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Axillary lymph node dissection (ALND); Breast cancer; Overall survival (OS); SINODAR ONE; Sentinel lymph node biopsy (SLNB)

Mesh：

Year:  2016        PMID： 27406897     DOI： 10.1016/j.breast.2016.06.016

Source DB:  PubMed          Journal:  Breast        ISSN： 0960-9776            Impact factor:   4.380


  13 in total

1.  A logistic regression model predicting high axillary tumour burden in early breast cancer patients.

Authors:  I Barco; M García Font; A García-Fernández; N Giménez; M Fraile; J M Lain; E Vallejo; S González; L Canales; J Deu; M C Vidal; M Rodríguez-Carballeira; A Pessarrodona; C Chabrera
Journal:  Clin Transl Oncol       Date:  2017-08-14       Impact factor: 3.405

Review 2.  What Is the Best Management of cN0pN1(sn) Breast Cancer Patients?

Authors:  Jana de Boniface; Marcus Schmidt; Jutta Engel; Marjolein L Smidt; Birgitte Vrou Offersen; Toralf Reimer
Journal:  Breast Care (Basel)       Date:  2018-09-05       Impact factor: 2.860

3.  Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial.

Authors:  T Reimer; A Stachs; V Nekljudova; S Loibl; S Hartmann; K Wolter; G Hildebrandt; B Gerber
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-02       Impact factor: 2.915

4.  Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.

Authors:  Arielle P Stafford; Tanya L Hoskin; Courtney N Day; Stacy B Sanders; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2022-04-22       Impact factor: 5.344

5.  Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial.

Authors:  Corrado Tinterri; Damiano Gentile; Wolfgang Gatzemeier; Andrea Sagona; Erika Barbieri; Alberto Testori; Valentina Errico; Alberto Bottini; Emilia Marrazzo; Carla Dani; Beatrice Dozin; Luca Boni; Paolo Bruzzi; Bethania Fernandes; Davide Franceschini; Ruggero Spoto; Rosalba Torrisi; Marta Scorsetti; Armando Santoro; Giuseppe Canavese
Journal:  Ann Surg Oncol       Date:  2022-05-12       Impact factor: 4.339

6.  Can Preoperative Ultrasonography and MRI Replace Sentinel Lymph Node Biopsy in Management of Axilla in Early Breast Cancer-a Prospective Study from a Tertiary Cancer Center.

Authors:  Sangram K Panda; Ashish Goel; Vikash Nayak; Saleem Shaik Basha; Pankaj K Pande; Kapil Kumar
Journal:  Indian J Surg Oncol       Date:  2019-04-27

7.  Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.

Authors:  Gilles Houvenaeghel; Monique Cohen; Pédro Raro; Jérémy De Troyer; Christine Tunon de Lara; Pierre Gimbergues; Tristan Gauthier; Christelle Faure-Virelizier; Véronique Vaini-Cowen; Stéphane Lantheaume; Claudia Regis; Emile Darai; Vivien Ceccato; Gauthier D'Halluin; Francesco Del Piano; Richard Villet; Eva Jouve; Bassoodéo Beedassy; Pierrick Theret; Philippe Gabelle; Cécile Zinzindohoue; Pierre Opinel; Catherine Marsollier-Ferrer; Caroline Dhainaut-Speyer; Pierre-Emmanuel Colombo; Eric Lambaudie; Agnès Tallet; Jean-Marie Boher
Journal:  BMC Cancer       Date:  2018-11-21       Impact factor: 4.430

8.  NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy.

Authors:  Corrado Tinterri; Giuseppe Canavese; Paolo Bruzzi; Beatrice Dozin
Journal:  Contemp Clin Trials Commun       Date:  2019-11-23

9.  A Radiation Oncologist's Guide to Axillary Management in Breast Cancer: A Walk Through the Trials.

Authors:  Julie K Jang; Elana R Sverdlik; Naomi R Schechter
Journal:  Curr Breast Cancer Rep       Date:  2019-09-14

10.  A National Survey of Breast Surgeons and Radiation Oncologists on Contemporary Axillary Management in Mastectomy Patients.

Authors:  Chandler S Cortina; Carmen Bergom; Morgan Ashley Craft; British Fields; Ruta Brazauskas; Adam Currey; Amanda L Kong
Journal:  Ann Surg Oncol       Date:  2021-07-10       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.